Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark.
The GLP-1 agonist failed to delay disease progression in patients in two …
The FDA has started a priority review of Otsuka’s triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.
Tenpoint Therapeutics landed an FDA approval for its presbyopia eye drop on Wednesday, entering a tricky commercial landscape for therapeutic alternatives to reading glasses and
ChenMed CEO Chris Chen said the primary care chain isn’t encouraging the use of GLP-1 drugs for weight loss after finding the medications led to
Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to
Veradermics, a biotech in late-stage testing with an oral version of Rogaine, is looking to raise $181.8 million in net proceeds from its proposed IPO.
Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark.
The GLP-1 agonist failed to delay disease progression in patients in two …